<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326558</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH-URO-001</org_study_id>
    <nct_id>NCT02326558</nct_id>
  </id_info>
  <brief_title>Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma</brief_title>
  <official_title>Comparison of Zero Ischemia Laparoscopic Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility, safety and efficiency of zero
      ischemia laparoscopic microwave ablation-assisted enucleation in comparison with conventional
      laparoscopic partial nephrectomy in the treatment of T1a renal cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microwave ablation has been widely used in the minimally-invasive treatment of renal tumors.
      Recently, a technique of laparoscopic microwave ablation-assisted renal tumor enucleation was
      developed, but the experience was preliminary. This study aims to evaluate the feasibility,
      safety and efficiency of this technique, particularly its role in the preservation of renal
      function, in comparison with conventional laparoscopic partial nephrectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute change in glomerular filtration rate (GFR) of the affected kidney</measure>
    <time_frame>baseline, 3 months and 12 months</time_frame>
    <description>measured by renal scintigraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>absolute change in eGFR of the affected kidney</measure>
    <time_frame>baseline, 3 months, 6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute change in total GFR</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>measured by renal scintigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood loss</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical margin</measure>
    <time_frame>1 month</time_frame>
    <description>assessed according to the pathology report of the operation specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>up to 6 months</time_frame>
    <description>number of participants with postoperative complications graded by Clavien- Dindo system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>microwave enucleation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic partial nephrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional laparoscopic partial nephrectomy with clamping of the renal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic microwave ablation-assisted enucleation</intervention_name>
    <arm_group_label>microwave enucleation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional laparoscopic partial nephrectomy</intervention_name>
    <arm_group_label>laparoscopic partial nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with sporadic, unilateral, newly diagnosed T1a presumed renal cell carcinoma

          -  exophytic cancer

          -  distance from the hilar renal vessels and urinary collecting system &gt;= 1cm

          -  patients with normal contralateral renal function (differential renal function of &gt;40%
             as determined by renal scintigraphy)

          -  patients giving consent to the participation in the current clinical trial

        Exclusion Criteria:

          -  patients with a history of other renal diseases, such as urinary lithiasis

          -  patients with a history of renal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Ran Huang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Huang Yi-Ran</investigator_full_name>
    <investigator_title>Chef of Urology</investigator_title>
  </responsible_party>
  <keyword>zero ischemia</keyword>
  <keyword>microwave</keyword>
  <keyword>ablation</keyword>
  <keyword>enucleation</keyword>
  <keyword>renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

